These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 31728838)

  • 21. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
    Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
    Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways.
    Cataldo D; Louis R; Michils A; Peché R; Pilette C; Schleich F; Ninane V; Hanon S
    J Asthma; 2021 Apr; 58(4):448-458. PubMed ID: 31928102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
    Laidlaw TM; Bachert C; Amin N; Desrosiers M; Hellings PW; Mullol J; Maspero JF; Gevaert P; Zhang M; Mao X; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
    Ann Allergy Asthma Immunol; 2021 May; 126(5):584-592.e1. PubMed ID: 33465455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis.
    Busse WW; Maspero JF; Lu Y; Corren J; Hanania NA; Chipps BE; Katelaris CH; FitzGerald JM; Quirce S; Ford LB; Rice MS; Kamat S; Khan AH; Jagerschmidt A; Harel S; Rowe P; Pirozzi G; Amin N; Ruddy M; Graham NMH; Teper A
    Ann Allergy Asthma Immunol; 2020 Nov; 125(5):565-576.e1. PubMed ID: 32474156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.
    Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
    Clin Exp Allergy; 2020 Apr; 50(4):442-452. PubMed ID: 31943429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma.
    Brusselle G; Quirce S; Papi A; Kuna P; Chipps BE; Hanania NA; Blaiss M; Msihid J; Jacob-Nara JA; Deniz Y; Rowe PJ; Gall R; Ortiz B; Djandji M; Radwan A
    J Allergy Clin Immunol Pract; 2023 Mar; 11(3):873-884.e11. PubMed ID: 36572184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
    Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps.
    Berger P; Menzies-Gow A; Peters AT; Kuna P; Rabe KF; Altincatal A; Soler X; Pandit-Abid N; Siddiqui S; Jacob-Nara JA; Deniz Y; Rowe PJ
    Ann Allergy Asthma Immunol; 2023 Feb; 130(2):215-224. PubMed ID: 36356712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
    Rabe KF; Nair P; Brusselle G; Maspero JF; Castro M; Sher L; Zhu H; Hamilton JD; Swanson BN; Khan A; Chao J; Staudinger H; Pirozzi G; Antoni C; Amin N; Ruddy M; Akinlade B; Graham NMH; Stahl N; Yancopoulos GD; Teper A
    N Engl J Med; 2018 Jun; 378(26):2475-2485. PubMed ID: 29782224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial.
    Sher LD; Wechsler ME; Rabe KF; Maspero JF; Daizadeh N; Mao X; Ortiz B; Mannent LP; Laws E; Ruddy M; Pandit-Abid N; Jacob-Nara JA; Gall R; Rowe PJ; Deniz Y; Lederer DJ; Hardin M
    Chest; 2022 Jul; 162(1):46-55. PubMed ID: 35217003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.
    Wechsler ME; Ruddy MK; Pavord ID; Israel E; Rabe KF; Ford LB; Maspero JF; Abdulai RM; Hu CC; Martincova R; Jessel A; Nivens MC; Amin N; Weinreich DM; Yancopoulos GD; Goulaouic H
    N Engl J Med; 2021 Oct; 385(18):1656-1668. PubMed ID: 34706171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dupilumab for the treatment of asthma.
    Santini G; Mores N; Malerba M; Mondino C; Anzivino R; Macis G; Montuschi P
    Expert Opin Investig Drugs; 2017 Mar; 26(3):357-366. PubMed ID: 28085503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps.
    Hoy SM
    Drugs; 2020 May; 80(7):711-717. PubMed ID: 32240527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis.
    Phinyo P; Krikeerati T; Vichara-Anont I; Thongngarm T
    J Allergy Clin Immunol Pract; 2024 Feb; 12(2):409-420. PubMed ID: 37972921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
    DuBuske L; Newbold P; Wu Y; Trudo F
    Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma.
    Weinstein SF; Katial R; Jayawardena S; Pirozzi G; Staudinger H; Eckert L; Joish VN; Amin N; Maroni J; Rowe P; Graham NMH; Teper A
    J Allergy Clin Immunol; 2018 Jul; 142(1):171-177.e1. PubMed ID: 29355679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
    Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.